PCSK9 Inhibitor Use in the Real World: Data From the National Patient‐Centered Research Network

BACKGROUND: PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors effectively lower LDL (low‐density lipoprotein) cholesterol and have been shown to reduce cardiovascular outcomes in high‐risk patients. We used real‐world electronic health record data to characterize use of PCSK9 inhibito...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Heart Assoc
Main Authors: Chamberlain, Alanna M., Gong, Yan, Shaw, Kathryn McAuliffe, Bian, Jiang, Song, Wen‐Liang, Linton, MacRae F., Fonseca, Vivian, Price‐Haywood, Eboni, Guhl, Emily, King, Jordan B., Shah, Rashmee U., Puro, Jon, Shenkman, Elizabeth, Pawloski, Pamala A., Margolis, Karen L., Hernandez, Adrian F., Cooper‐DeHoff, Rhonda M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512121/
https://ncbi.nlm.nih.gov/pubmed/31020929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.118.011246
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados